Proteins.1

Based in Finland, Proteins. 1 Oy operates a pioneering enzyme-free multiomics platform that enhances the detection of proteins, DNA, and RNA for advanced molecular diagnostics. Proteins. 1 Oy focuses on innovative molecular diagnostics, utilizing a proprietary platform originating from VTT.

The company is headquartered in Espoo, Finland. In April 2026, Proteins. 1 secured EUR 4. 7 million in pre-seed funding, co-led by Lifeline Ventures and Cloudberry, with participation from VTT Technical Research Centre of Finland Ltd.

and Business Finland Venture Capital. Proteins. 1 specializes in a groundbreaking physics-based, enzyme-free multiomics platform designed to facilitate ultra-sensitive molecular detection of proteins, DNA, and RNA. The core functionality of its offering allows for the detection of previously invisible protein signals, aiming to enhance early diagnosis, biomarker research, and drug discovery processes.

This innovative technology enables users to detect diseases before they manifest visibly, thus accelerating the drug development timeline and unlocking new biological insights. The platform caters primarily to research institutions, pharmaceutical companies, and biotechnology firms that require advanced detection capabilities in their scientific endeavors. Proteins. 1 is positioned within multiple geographical markets, including North America, Europe, and Asia, where it serves a diverse clientele focused on advancing healthcare solutions through molecular research.

Proteins. 1 generates revenue primarily through B2B transactions, partnering with research institutions and pharmaceutical companies that utilize its enzyme-free detection technology. The company offers structured agreements that may include subscription models for access to its platform and services, as well as potential collaborations on research and development projects. Specific pricing plans are tailored to the individual needs of clients, reflecting the customized nature of the technology's applications in various research settings.

The flagship product, which embodies the company’s innovative approach, is central to these revenue streams, attracting clients who seek to improve their diagnostic and drug discovery capabilities. Overall, the transaction structure facilitates long-term partnerships, ensuring ongoing revenue generation through continued use and potential expansion of services within the client organizations. Following its recent funding round in April 2026, Proteins. 1 plans to utilize the EUR 4.

7 million raised to enhance its VTT-originated technology and extend its molecular diagnostics capabilities for earlier disease signal detection. The company aims to launch new products focused on improving detection methodologies, although specific release dates have not been disclosed. Additionally, Proteins. 1 is targeting expansion into markets within North America and Asia by 2027, aiming to broaden its reach in the healthcare sector.